MPM Capital

MPM Capital

CNET

Best DNA test in 2020: 23andMe vs. AncestryDNA and more

$115,000,000 Venture capital
FinSMEs

Dyne Therapeutics Raises $115M in Equity Financing

Tech Insider

Apple, Google, 23andMe, and others are fighting COVID-19, from wearables to faster CT scans to contact tracing

Xconomy

Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline

$98,500,000 Venture capital (Series B)
FinSMEs

Cullinan Oncology Closes $98.5M Series B Financing Round

Xconomy

After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO

MedCity News

Alexion plunks down $1.4B to acquire Portola Pharmaceuticals

$170,000,000 Venture capital (Series B)
FinSMEs

ElevateBio Raises $170M in Series B Financing

TechCrunch

Cell and gene therapy startup ElevateBio raises $170 million

$80,000,000 Venture capital (Series A)
Xconomy

With $80M, ReCode Looks to Advance RNA Therapies for Lung Diseases

ZDNet

Privacy worries cited as possible reason for DNA test firm 23andMe's sales downturn

USA TODAY Tech

23andMe reportedly laid off 14% of its workforce as people stop buying DNA testing kits

SiliconBeat

23andMe cuts 100 jobs as DNA testing market slows

Forbes Tech

23andMe Lays Off 14% Of Workforce Amid Declining DNA Test Sales

CNBC Tech , Recode , The Verge

23andMe lays off 100 people as DNA test sales decline, CEO says she was 'surprised' to see market turn

TechCrunch

Layoffs reach 23andMe after hitting Mozilla and the Vision Fund portfolio

The Verge , New Scientist

23andMe sold the rights to a drug it developed from its genetic database

TechCrunch

Congratulations 23andMe users, your genes are finally helping the company make drugs

CNBC Tech

Fertility start-up Celmatix sues former business partner 23andMe for $100 million in damages

the home of AI info

Comparing of MacroGenics Inc. (MGNX) and Minerva Neurosciences Inc. (NASDAQ:NERV)